20 December 2019 
EMA/483758/2020 
Human Medicines Evaluation Division 
Statement indicating compliance with the agreed 
completed paediatric investigation plan  
Medicinal product  
Hemlibra/ emicizumab 
Pharmaceutical form(s): 
Strength(s): 
Route(s) of administration: 
Packaging and package size(s): 
Number(s) in the Community 
Register of Medicinal Products: 
See Annex A  
See Annex A 
See Annex A 
See Annex A 
See Annex A 
Marketing authorisation holder (MAH): 
Name and address of the MAH:  Roche Registration GmbH 
Emil-Barell-Strasse 1 
79639 Grenzach-Wyhlen 
GERMANY 
Procedure  
Procedure number: 
EMEA/H/C/004406/IB/0015 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
-the development of this product has complied with all measures in the agreed paediatric investigation 
plan {decision number PIP EMEA-C-001839-PIP01-15}. For the purpose of the application of Article 45(3) 
of Regulation EC (No) 1901/2006, significant studies in the agreed paediatric investigation plan  have 
been completed after the entry into force of that Regulation, 
To include a statement indicating compliance with the agreed completed PIP EMEA-C-001839-PIP01-15, 
for: Treatment of hereditary factor VIII deficiency. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
 An agency of the European Union      
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The outcomes of the compliance checks with PIP: EMEA- C-001839-PIP01-15, are provided within this 
application, as follow:  
- Partial compliance check 1 granted on the 19.05.2017 
- Full compliance check, granted on the 26.04.2019 
-the Summary of Product Characteristics adopted by CHMP reflects the results of studies conducted in 
compliance with this agreed paediatric investigation plan.> 
